The tools that have driven decades of progress against malaria are under threat. Antimalarial medicines are showing early signs of reduced effectiveness, while mosquitoes are developing resistance to commonly used insecticides. Without urgent action, we risk losing the tools that have saved millions of lives to resistance.
Resistance to frontline antimalarial treatments is no longer a distant threat. In countries like Rwanda, health workers are already seeing the consequences – patients returning with persistent infections despite receiving treatment and rising cases in places where progress has been made.
Artemisinin-based combination therapies (ACTs) have transformed malaria control and contributed to a significant reduction in malaria deaths since 2000. But as resistance to the most widely used drugs spreads, our response needs to focus on protecting these medicines before they stop working.
Innovation is our defense
Protecting the tools we have requires constant innovation – not just new products, but new strategies to slow resistance before it takes hold.
In Rwanda – and across five other countries – we are working with Jhpiego and other partners to stay ahead of resistance. By supporting health systems to use multiple antimalarial treatments, instead of relying on a single first-line treatment, we can ensure no one drug gets overused. Modelling suggests that a ‘multiple first-line therapy’ approach can help slow the spread of resistance and protect the effectiveness of existing medicines.
Watch this video to hear more from partners in Rwanda on how antimalarial drug resistance is emerging and evolving, and how we’re working to protect the tools we have.